Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 03, 2021 / 07:40PM GMT
Release Date Price: $88 (-0.45%)
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Hey, everyone. Thanks for joining us at the Sarepta fireside chat at the Cowen 2021 Health Care Conference. Hopefully, our first and only virtual health care conference for Cowen.

With us from Sarepta, we have CEO, Doug Ingram; CFO, Ian Estepan; and CMO, Gilmore O'Neill, who I'm sure most of you know.

Questions & Answers

Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

So Doug, let's get started. I guess, Doug and Gilmore. So the last major milestone you have is the top line for the Phase II 102 study from your DMD gene therapy. You missed on the top line NSAA analysis because there's some pretty significant baseline imbalances between age cohorts, which were not stratified for baseline block. One question I've gotten from investors a lot is why didn't you stratify? And if you could, from there, just tell us how you're doing, what's the latest from the crossover patients and how

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot